Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart vs IVIg in adult CIDP (emvigorate)
CTR20255118Phase 3Terminated
- Sponsor
- 不适用/ 百时益医药研发（北京）有限公司
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by 不适用/ 百时益医药研发（北京）有限公司. Started Jan 2026; status: terminated.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on CTR20255118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255118.